• safety of therapy [ Time Frame: overall study ] [ Designated as safety issue: Yes ]
  
• efficacy of therapy [ Time Frame: overall study ] [ Designated as safety issue: No ]
  

Primary Objectives

• To assess the overall safety of sorafenib when administered with "the 2DOC regimen" capecitabine and oxaliplatin in patients with advanced or metastatic pancreas or biliary tract cancers.
• To define the dose limiting toxicity and maximally tolerated dose of this combination.
• To assess the clinical response rate (stable, partial and complete responses) of the combination in patients with advanced or metastatic pancreas or biliary tract cancers.

Secondary Objectives

• To define the time to progression and overall survival for patients treated with this regimen.
• To evaluate the congruency of the Adverse Events Self-Report Survey in determining patient reported side effects of treatment

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed locally advanced inoperable or metastatic adenocarcinoma of the pancreas or biliary tract who have not previously received more than one systemic treatment for their disease.
• Age at least 18 years old
• ECOG performance status 0-2.
• Patients must have adequate organ and marrow function as defined below:
• WBC at least 3,000
• ANC at least 1,500
• PLT at least 100,000
• total bilirubin must be less than 2.5 x institutional upper limit of norm
• AST(SGOT)/ALT(SGPT) must be less than 5 X institutional upper limit of normal
• creatinine clearance must be greater than 50 mL/min as calculated by the Cockroft-Gault formula
• Patients with ≤ grade 2 (CTC 3.0) neuropathy.
• At least one measurable lesion as defined by RECIST criteria
• The effects of oxaliplatin, capecitabine and sorafenib on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because DNA alkylating agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Because the risk of toxicity in nursing infants secondary to oxaliplatin treatment of the mother is unknown but may be harmful, breastfeeding should be discontinued if the mother is treated with oxaliplatin.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• No concomitant radiation therapy, or other systemic cancer therapies.
• Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other toxicities.
• History of allergy to platinum compounds, capecitabine, sorafenib or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy.
• Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months, symptomatic congestive heart failure, unstable angina pectoris within 3 months prior to entry study, myocardial infarction within 6 months prior to study entry, ongoing cardiac arrhythmia (excluding atrial fibrillation), uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 90 mmHg, despite optimal medical management), pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug, or any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug, serious non-healing wound, ulcer, or bone fracture, evidence or history of bleeding diathesis or coagulopathy.
• Pregnant or nursing women are excluded from this study because oxaliplatin, capecitabine and sorafenib is a DNA alkylating agent with the potential for teratogenic or abortifacient effects. Female patients of reproductive potential must have a negative urine or serum pregnancy test within two weeks prior to enrolling.
• Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.
• Because of drug interactions with sorafenib, use of St. John's Wort or rifampin (rifampicin) is contraindicated. Patients may discontinue the use of these drugs to become eligible for the study
• Any condition that impairs patient's ability to swallow whole pills.
• HIV-positive patients receiving anti-retroviral therapy (HAART) are excluded from the study because of possible pharmacokinetic interactions.
• Second malignancy within the past 3 years (excluding nonmelanoma skin cancer and in situ cancers) that has not been treated with curative intent and is not currently without evidence of disease,
• Patients with known gastrointestinal malabsorption syndromes are excluded as this concurrent illness will affect absorption of the oral medications.